1. A patient newly diagnosed with T2DM is started on lifestyle management and pharmacotherapy based on the ADA guidelines. What is his general A1C target and when will his A1C be checked again?
A. < 6.5%, 3 months
B. < 7%, 3 months
C. < 6.5%, 1 month
D. < 7%, 1 month
2. Which of the following represents first-line therapy for T2DM management in both the ADA and AACE guidelines?
A. Lifestyle management + metformin
B. Lifestyle management + insulin
C. Lifestyle management + a sulfonylurea
D. Lifestyle management alone
3. A patient requests that you cancel her refill of metformin 1000 mg. Since she started taking this medication last month, she has had GI discomfort and diarrhea. She states that she is certain she is allergic to it. You should:
A. Cancel the refills and add a metformin allergy to her patient profile
B. Counsel her to try taking half a tablet with food and increase her dose more slowly to avoid the side effects
C. Alert the pharmacist for a patient consultation to identify if changes in dose, titration, or formulation can mitigate the side effects
D. Advise the patient to seek medical help right aware as she is experiencing a rare, severe side effect that requires additional intervention
4. Which of the following medications works in the kidneys to increase the urinary output of glucose?
A. Pioglitazone
B. Alogliptin
C. Glyburide
D. Canagliflozin
5. Which of the following classes of medications carries a high risk of hypoglycemia?
A. DPP-4 inhibitors
B. Metformin
C. Sulfonylureas
D. Alpha-glucosidase inhibitors
6. Which of the following medications affects the presence of incretin hormones to increase insulin secretion, decrease glucagon secretion, slow gastric emptying, and increase satiety?
A. Nateglinide
B. Ertugliflozin
C. Linagliptin
D. Colesevelam
7. What is the mechanism of action of thiazolidinediones (TZDs)?
A. TZDs sensitize adipose and muscle tissues to the action of insulin
B. TZDs inhibit an enzyme in the small intestine that breaks down complex molecules into absorbable sugars
C. TZDs are non-sulfonylurea insulin secretagogues
D. The mechanism of action of TZDs is not well understood
8. A patient is picking up her maintenance medication refills and a new antibiotic. She complains that this is her third urinary tract infection in two months. Which of the following medications in her profile should prompt a consultation with the pharmacist?
A. Metformin
B. Saxagliptin
C. Bromocriptine
D. Dapagliflozin
9. At diagnosis, a patient's A1C is 9.2%. Given the expected A1C reduction of most oral diabetes medications, what type of therapy regimen is the patient likely to require to reach a typical A1C goal listed in the guidelines?
A. Lifestyle management alone
B. Lifestyle management + monotherapy with metformin
C. Lifestyle management + dual or triple therapy (metformin + other classes of medications)
D. This patient can only be managed using injectable therapies such as insulin
10. Which of the following combination products contains an SGLT2 inhibitor and a DPP-4 inhibitor?
A. Glyxambi
B. Kombiglyze
C. Synjardy
D. Xigduo
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Will the information presented cause you to change your practice?
A. Yes
B. No
23. Are you committed to making these changes?
A. Yes
B. No
24. As a result of this activity, did you learn something new?
A. Yes
B. No
25. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
26. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20